Optimizing long-term stability of siRNA using thermoassemble ionizable reverse pluronic-Bcl2 micelleplexes

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapeutics

Background:

• Previous siRNA delivery systems face challenges with stability and targeted delivery.
• Developing effective nanocarriers is crucial for advancing cancer gene therapy.

Purpose of the Study:

• To develop and characterize a novel Thermosassemble Ionizable Reverse Pluronic (TIRP) nanocarrier for enhanced siRNA delivery.
• To evaluate the potential of TIRP-Bcl2 for targeting oncogenic pathways and treating glioblastoma.

Main Methods:

• Self-assembly of TIRP-Bcl2 into micelle structures with controlled nanodiameter.
• Assessment of siRNA loading capacity, colloidal stability, and release profiles.
• Evaluation of thermoresponsive behavior for enhanced tissue penetration and cellular uptake.
• Investigation of blood-brain barrier transport capabilities.

Main Results:

• TIRP-Bcl2 self-assembles into stable micelles (75.8 ± 5.7 nm) with high siRNA loading and 8-month stability at 4°C.
• Controlled siRNA release over 180 hours and enhanced gene silencing efficacy in cancer cells.
• Demonstrated ability to cross the blood-brain barrier, showing potential for glioblastoma treatment.
• Thermoresponsive properties facilitated improved deep tissue penetration and tumor microenvironment targeting.

Conclusions:

• The TIRP platform offers a promising solution for long-term, stable siRNA delivery with enhanced therapeutic potential.
• TIRP-Bcl2 exhibits significant promise for personalized cancer therapies, particularly for glioblastoma.
• Further research and clinical translation are warranted for this innovative nanocarrier system.